Possible Beneficial Effects of Hydrolyzable Tannins Deriving from

anticancer effects antioxidant effects cardioprotective effects chestnuts hydrolyzable tannins lipid metabolism nutraceuticals

Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
22 Dec 2023
Historique:
received: 03 11 2023
revised: 13 12 2023
accepted: 19 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

Hydrolyzable tannins (HTs) deriving from chestnuts have demonstrated, through numerous studies, the ability to exert multiple beneficial effects, including antioxidant and antimicrobial effects, on the lipid metabolism and cancer cells. The latter effect is very fascinating, since different polyphenols deriving from chestnuts were able to synergistically induce the inhibition of cancerous cells through multiple pathways. Moreover, the main mechanisms by which tannins induce antioxidant functions include: the reduction in oxidative stress, the ability to scavenge free radicals, and the modulation of specific enzymes, such as superoxide dismutase. HTs have also been shown to exert significant antimicrobial activity by suppressing microbial growth. The actions on the lipid metabolism are several, among which is the inhibition of lipid accumulation. Thus, tannins seem to induce a cardioprotective effect. In fact, through various mechanisms, such as the relaxation of the vascular smooth muscle, HTs were proven to be efficient against arterial hypertension. Therefore, the great number of studies in this field prove the growing interest on the utilization of natural bioactive compounds, such as HTs deriving from natural sources or obtained by circular economy models, as potential nutraceuticals or adjuvants therapies.

Identifiants

pubmed: 38201875
pii: nu16010045
doi: 10.3390/nu16010045
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Giulia Marrone (G)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Manuela Di Lauro (M)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Francesco Izzo (F)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Kevin Cornali (K)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Claudia Masci (C)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Chiara Vita (C)

QuMAP (Quality of Goods and Product Reliability), University of Florence, PIN, 59100 Prato, Italy.
Department of Economics, Management and Business Law, University of Bari "Aldo Moro", Piazza Umberto I, 70121 Bari, Italy.

Francesco Occhiuto (F)

Ph.D. School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Nicola Di Daniele (N)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Fondazione Leonardo per le Scienze Mediche Onlus, Policlinico Abano, 35031 Abano Terme, Italy.

Antonino De Lorenzo (A)

Section of Clinical Nutrition and Nutrigenomic, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

Annalisa Noce (A)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
UOSD Nephrology and Dialysis, Policlinico Tor Vergata, 00133 Rome, Italy.

Classifications MeSH